The Motley Fool takes a closer look Covance's earnings and free cash flow

First-quarter financial results for Covance ($CVD) were a mixed bag that showed growth in one field (late-stage development), and decline in others (early-stage development and toxicology). But while the CRO posted overall revenue growth, Seth Jayson from The Motley Fool asks investors to take a closer look at Covance's free cash flow. "An increase in cash flow based on stiffing your suppliers (by increasing accounts payable for the short term) or shortchanging Uncle Sam on taxes will come back to bite investors later," the article says. Article

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.